Parkinson’s UK is pleased to announce the release of the next tranche of funding to US company Neurolixis to continue final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia.
In January 2018, Parkinson’s UK announced funding of more than $1million in funding to enable the NLX-112 program to move through the necessary regulatory steps in preparation for clinical trials.
Dr Mark Varney, Co-founder, President and Chief Executive Officer at Neurolixis, said:
“We’re very pleased with the progress that is being made in this project which has successfully met the first milestones and will now continue into the next stage of the workplan. If things continue to progress positively, we hope that clinical trials to test the drug in people affected by Parkinson’s will start in the next 12 months.”